{"entity":{"id":"nct06189209","kind":"trial","name":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","aka":[],"tldr":"A phase 2 trial of Tenalisib in triple-negative breast cancer, run by Rhizen Pharmaceuticals SA, now recruiting.","summary":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) is a phase 2 interventional study registered as NCT06189209 by Rhizen Pharmaceuticals SA, with 40 participants planned, started 2024-03-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: Tenalisib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06189209","url":"https://clinicaltrials.gov/study/NCT06189209"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06189209","phase":"2","setting":"A Phase II, Multi-center, Single-arm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K δ/γ, and SIK3 Inhibitor, in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","sponsor":"Rhizen Pharmaceuticals SA","enrolled":40,"outcomes":[]},"route":"/trials/nct06189209/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"tenalisib","kind":"drug","name":"Tenalisib","route":"/drugs/tenalisib/"}]}}